Загрузка...
Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis
BACKGROUND AND PURPOSE: Liver fibrosis is a major cause of liver‐related mortality and, so far, no effective antifibrotic drug is available. Galunisertib, a TGF‐β receptor type I kinase inhibitor, is a potential candidate for the treatment of liver fibrosis. Here, we evaluated the potency of galunis...
Сохранить в:
| Опубликовано в: : | Br J Pharmacol |
|---|---|
| Главные авторы: | , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5573419/ https://ncbi.nlm.nih.gov/pubmed/28691737 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.13945 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|